Evaluation of Tumor Burden Response to Single-cycle of Lu-177 PSMA Treatment with Whole Body Scintigraphic Planar Images in Prostate Cancer Patients

Emine Acar; Ayşegül Aksu; Ender Berat Ellidokuz; Yasemin Başbınar; Gamze Çapa Kaya

doi:10.30621/jbachs.1189713

Research Article

BibTex

RIS

Cite

Evaluation of Tumor Burden Response to Single-cycle of Lu-177 PSMA Treatment with Whole Body Scintigraphic Planar Images in Prostate Cancer Patients

Year 2023, Volume: 7 Issue: 1, 471 - 478, 31.01.2023

Emine Acar , Ayşegül Aksu , Ender Berat Ellidokuz , Yasemin Başbınar , Gamze Çapa Kaya

https://doi.org/10.30621/jbachs.1189713

Abstract

The aim of this study; evaluation of treatment response and survival with post-therapy images in patients who received one cycle of Lu-177 PSMA I&T treatment.

Keywords

prostate cancer, Lu-177 PSMA, radioligand therapy, scintigraphy

References

1. Kind F, Fassbender TF, Andrieux G, Boerries M, Meyer PT, Ruf J. Early PSA Change after [(177)Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival. Cancers (Basel). 2021;14(1).
2. Gupta M, Karthikeyan G, Choudhury PS, Sharma A, Singh A, Rawal S. Is (177)Lu-PSMA an effective treatment modality for mCRPC patients with bone and visceral metastasis? Hell J Nucl Med. 2020;23(3):312-20.
3. Baumann R, Koncz M, Luetzen U, Krause F, Dunst J. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT. Strahlenther Onkol. 2018;194(4):318-24.
4. Asif S, Teply BA. Biomarkers for Treatment Response in Advanced Prostate Cancer. Cancers (Basel). 2021;13(22).
5. Donin NM, Reiter RE. Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. J Nucl Med. 2018;59(2):177-82.
6. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091-103.
7. Khreish F, Ghazal Z, Marlowe RJ, et al. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2022;49(3):1075-85.
8. Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(3):471-95.
9. Nioche C, Orlhac F, Boughdad S, et al. LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res. 2018;78(16):4786-9.
10. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, Witten IH. The WEKA data mining software: an update. SIGKDD Explor Newsl. 2009;11(1):10-8.
11. Dorff TB, Fanti S, Farolfi A, Reiter RE, Sadun TY, Sartor O. The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer. Am Soc Clin Oncol Educ Book. 2019;39:321-30.
12. Kletting P, Thieme A, Eberhardt N, et al. Modeling and Predicting Tumor Response in Radioligand Therapy. J Nucl Med. 2019;60(1):65-70.
13. Grubmüller B, Senn D, Kramer G, et al. Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(5):1063-72.
14. Liu C, Liu T, Zhang N, et al. (68)Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2018;45(11):1852-61.
15. Michalski K, Klein C, Brueggemann T, Meyer PT, Jilg CA, Ruf J. Assessing Response to [(177)Lu]PSMA Radioligand Therapy using modified PSMA PET Progression Criteria. J Nucl Med. 2021;62(12):1741-6.
16. Prasad V, Huang K, Prasad S, Makowski MR, Czech N, Brenner W. In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2(nd) Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With (177)Lu-PSMA. Front Oncol. 2021;11:578093.
17. Rasul S, Hacker M, Kretschmer-Chott E, et al. Clinical outcome of standardized (177)Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. Eur J Nucl Med Mol Imaging. 2020;47(3):713-20.
18. Zacherl MJ, Gildehaus FJ, Mittlmeier L, et al. First Clinical Results for PSMA-Targeted α-Therapy Using (225)Ac-PSMA-I&T in Advanced-mCRPC Patients. J Nucl Med. 2021;62(5):669-74.
19. Rathke H, Giesel FL, Flechsig P, et al. Repeated (177)Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. J Nucl Med. 2018;59(3):459-65.
20. Han S, Woo S, Kim YI, et al. Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2021;11(4).
21. Rathke H, Holland-Letz T, Mier W, et al. Response Prediction of (177)Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase. J Nucl Med. 2020;61(5):689-95.
22. Sadaghiani MS, Sheikhbahaei S, Werner RA, et al. (177) Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis. Prostate. 2022;82(7):826-35.
23. Sun M, Niaz MO, Nelson A, Skafida M, Niaz MJ. Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer. Cureus. 2020;12(6):e8921.
24. Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet J. Radiation Dosimetry in (177)Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors. J Nucl Med. 2020;61(7):1030-6.
25. Maffey-Steffan J, Scarpa L, Svirydenka A, et al. The (68)Ga/(177)Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up. Eur J Nucl Med Mol Imaging. 2020;47(3):695-712.
26. Yordanova A, Linden P, Hauser S, et al. Outcome and safety of rechallenge [(177)Lu]Lu-PSMA-617 in patients with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(5):1073-80.
27. Kelk E, Ruuge P, Rohtla K, Poksi A, Kairemo K. Radiomics Analysis for (177)Lu-DOTAGA-(l-y)fk(Sub-KuE) Targeted Radioligand Therapy Dosimetry in Metastatic Prostate Cancer-A Model Based on Clinical Example. Life (Basel). 2021;11(2).
28. Manafi-Farid R, Harsini S, Saidi B, et al. Factors predicting biochemical response and survival benefits following radioligand therapy with [(177)Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. Eur J Nucl Med Mol Imaging. 2021;48(12):4028-41.
29. O'Dwyer E, Bodei L, Morris MJ. The Role of Theranostics in Prostate Cancer. Semin Radiat Oncol. 2021;31(1):71-82.
30. Sorace AG, Elkassem AA, Galgano SJ, et al. Imaging for Response Assessment in Cancer Clinical Trials. Semin Nucl Med. 2020;50(6):488-504.

Year 2023, Volume: 7 Issue: 1, 471 - 478, 31.01.2023

Emine Acar , Ayşegül Aksu , Ender Berat Ellidokuz , Yasemin Başbınar , Gamze Çapa Kaya

https://doi.org/10.30621/jbachs.1189713

Abstract

References

1. Kind F, Fassbender TF, Andrieux G, Boerries M, Meyer PT, Ruf J. Early PSA Change after [(177)Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival. Cancers (Basel). 2021;14(1).
2. Gupta M, Karthikeyan G, Choudhury PS, Sharma A, Singh A, Rawal S. Is (177)Lu-PSMA an effective treatment modality for mCRPC patients with bone and visceral metastasis? Hell J Nucl Med. 2020;23(3):312-20.
3. Baumann R, Koncz M, Luetzen U, Krause F, Dunst J. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT. Strahlenther Onkol. 2018;194(4):318-24.
4. Asif S, Teply BA. Biomarkers for Treatment Response in Advanced Prostate Cancer. Cancers (Basel). 2021;13(22).
5. Donin NM, Reiter RE. Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. J Nucl Med. 2018;59(2):177-82.
6. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091-103.
7. Khreish F, Ghazal Z, Marlowe RJ, et al. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2022;49(3):1075-85.
8. Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(3):471-95.
9. Nioche C, Orlhac F, Boughdad S, et al. LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res. 2018;78(16):4786-9.
10. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, Witten IH. The WEKA data mining software: an update. SIGKDD Explor Newsl. 2009;11(1):10-8.
11. Dorff TB, Fanti S, Farolfi A, Reiter RE, Sadun TY, Sartor O. The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer. Am Soc Clin Oncol Educ Book. 2019;39:321-30.
12. Kletting P, Thieme A, Eberhardt N, et al. Modeling and Predicting Tumor Response in Radioligand Therapy. J Nucl Med. 2019;60(1):65-70.
13. Grubmüller B, Senn D, Kramer G, et al. Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(5):1063-72.
14. Liu C, Liu T, Zhang N, et al. (68)Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2018;45(11):1852-61.
15. Michalski K, Klein C, Brueggemann T, Meyer PT, Jilg CA, Ruf J. Assessing Response to [(177)Lu]PSMA Radioligand Therapy using modified PSMA PET Progression Criteria. J Nucl Med. 2021;62(12):1741-6.
16. Prasad V, Huang K, Prasad S, Makowski MR, Czech N, Brenner W. In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2(nd) Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With (177)Lu-PSMA. Front Oncol. 2021;11:578093.
17. Rasul S, Hacker M, Kretschmer-Chott E, et al. Clinical outcome of standardized (177)Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. Eur J Nucl Med Mol Imaging. 2020;47(3):713-20.
18. Zacherl MJ, Gildehaus FJ, Mittlmeier L, et al. First Clinical Results for PSMA-Targeted α-Therapy Using (225)Ac-PSMA-I&T in Advanced-mCRPC Patients. J Nucl Med. 2021;62(5):669-74.
19. Rathke H, Giesel FL, Flechsig P, et al. Repeated (177)Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. J Nucl Med. 2018;59(3):459-65.
20. Han S, Woo S, Kim YI, et al. Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2021;11(4).
21. Rathke H, Holland-Letz T, Mier W, et al. Response Prediction of (177)Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase. J Nucl Med. 2020;61(5):689-95.
22. Sadaghiani MS, Sheikhbahaei S, Werner RA, et al. (177) Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis. Prostate. 2022;82(7):826-35.
23. Sun M, Niaz MO, Nelson A, Skafida M, Niaz MJ. Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer. Cureus. 2020;12(6):e8921.
24. Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet J. Radiation Dosimetry in (177)Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors. J Nucl Med. 2020;61(7):1030-6.
25. Maffey-Steffan J, Scarpa L, Svirydenka A, et al. The (68)Ga/(177)Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up. Eur J Nucl Med Mol Imaging. 2020;47(3):695-712.
26. Yordanova A, Linden P, Hauser S, et al. Outcome and safety of rechallenge [(177)Lu]Lu-PSMA-617 in patients with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(5):1073-80.
27. Kelk E, Ruuge P, Rohtla K, Poksi A, Kairemo K. Radiomics Analysis for (177)Lu-DOTAGA-(l-y)fk(Sub-KuE) Targeted Radioligand Therapy Dosimetry in Metastatic Prostate Cancer-A Model Based on Clinical Example. Life (Basel). 2021;11(2).
28. Manafi-Farid R, Harsini S, Saidi B, et al. Factors predicting biochemical response and survival benefits following radioligand therapy with [(177)Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. Eur J Nucl Med Mol Imaging. 2021;48(12):4028-41.
29. O'Dwyer E, Bodei L, Morris MJ. The Role of Theranostics in Prostate Cancer. Semin Radiat Oncol. 2021;31(1):71-82.
30. Sorace AG, Elkassem AA, Galgano SJ, et al. Imaging for Response Assessment in Cancer Clinical Trials. Semin Nucl Med. 2020;50(6):488-504.

There are 30 citations in total.

Details

Primary Language	English
Subjects	Health Care Administration
Journal Section	Research Article
Authors	Emine Acar 0000-0002-6861-8814 Ayşegül Aksu 0000-0002-6239-0660 Ender Berat Ellidokuz 0000-0001-5863-3298 Yasemin Başbınar 0000-0001-9439-2217 Gamze Çapa Kaya 0000-0002-1256-7325
Publication Date	January 31, 2023
Submission Date	October 18, 2022
Published in Issue	Year 2023 Volume: 7 Issue: 1

Cite

APA	Acar, E., Aksu, A., Ellidokuz, E. B., Başbınar, Y., et al. (2023). Evaluation of Tumor Burden Response to Single-cycle of Lu-177 PSMA Treatment with Whole Body Scintigraphic Planar Images in Prostate Cancer Patients. Journal of Basic and Clinical Health Sciences, 7(1), 471-478. https://doi.org/10.30621/jbachs.1189713
AMA	Acar E, Aksu A, Ellidokuz EB, Başbınar Y, Çapa Kaya G. Evaluation of Tumor Burden Response to Single-cycle of Lu-177 PSMA Treatment with Whole Body Scintigraphic Planar Images in Prostate Cancer Patients. JBACHS. January 2023;7(1):471-478. doi:10.30621/jbachs.1189713
Chicago	Acar, Emine, Ayşegül Aksu, Ender Berat Ellidokuz, Yasemin Başbınar, and Gamze Çapa Kaya. “Evaluation of Tumor Burden Response to Single-Cycle of Lu-177 PSMA Treatment With Whole Body Scintigraphic Planar Images in Prostate Cancer Patients”. Journal of Basic and Clinical Health Sciences 7, no. 1 (January 2023): 471-78. https://doi.org/10.30621/jbachs.1189713.
EndNote	Acar E, Aksu A, Ellidokuz EB, Başbınar Y, Çapa Kaya G (January 1, 2023) Evaluation of Tumor Burden Response to Single-cycle of Lu-177 PSMA Treatment with Whole Body Scintigraphic Planar Images in Prostate Cancer Patients. Journal of Basic and Clinical Health Sciences 7 1 471–478.
IEEE	E. Acar, A. Aksu, E. B. Ellidokuz, Y. Başbınar, and G. Çapa Kaya, “Evaluation of Tumor Burden Response to Single-cycle of Lu-177 PSMA Treatment with Whole Body Scintigraphic Planar Images in Prostate Cancer Patients”, JBACHS, vol. 7, no. 1, pp. 471–478, 2023, doi: 10.30621/jbachs.1189713.
ISNAD	Acar, Emine et al. “Evaluation of Tumor Burden Response to Single-Cycle of Lu-177 PSMA Treatment With Whole Body Scintigraphic Planar Images in Prostate Cancer Patients”. Journal of Basic and Clinical Health Sciences 7/1 (January 2023), 471-478. https://doi.org/10.30621/jbachs.1189713.
JAMA	Acar E, Aksu A, Ellidokuz EB, Başbınar Y, Çapa Kaya G. Evaluation of Tumor Burden Response to Single-cycle of Lu-177 PSMA Treatment with Whole Body Scintigraphic Planar Images in Prostate Cancer Patients. JBACHS. 2023;7:471–478.
MLA	Acar, Emine et al. “Evaluation of Tumor Burden Response to Single-Cycle of Lu-177 PSMA Treatment With Whole Body Scintigraphic Planar Images in Prostate Cancer Patients”. Journal of Basic and Clinical Health Sciences, vol. 7, no. 1, 2023, pp. 471-8, doi:10.30621/jbachs.1189713.
Vancouver	Acar E, Aksu A, Ellidokuz EB, Başbınar Y, Çapa Kaya G. Evaluation of Tumor Burden Response to Single-cycle of Lu-177 PSMA Treatment with Whole Body Scintigraphic Planar Images in Prostate Cancer Patients. JBACHS. 2023;7(1):471-8.

Download Cover Image

Article Files

Full Text